Adjunctive Therapy for Kidney Stone Management No Longer in Shortage

The drug is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection
The drug is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection

The Food and Drug Administration (FDA) announced that Mission Pharmacal has resolved the shortage of Lithostat (acetohydroxamic acid) tablets.

Lithostat had been in shortage since July 2014. The drug is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. Acetohydroxamic acid (AHA) reversibly inhibits the bacterial enzyme urease, thereby inhibiting the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms. The reduced ammonia levels and decreased pH enhance the effectiveness of antimicrobial agents and allow an increased cure rate of these infections. 

Related Articles

In clinical trials, the use of AHA allowed successful antibiotic treatment of urea-splitting Proteus infections after surgical removal of struvite stones in patients not cured by three months of antibacterial treatment alone and also reduced the rate of stone growth in patients who were not candidates for surgical removal of stones. 

Lithostat is available for oral administration in 250mg tablets.

For more information visit MissionPharmacal.com.